|
Widely referred to as the "morning after cream", Dimercine is currently undergoing clinical trials to access it's ability to reverse the DNA damage inflicted upon skin cells by UV rays.
It's estimated that 10% of all damage to cellular DNA is caused by ultra violet light. When exposed to the sun, ultra violet rays create free radicals, which inflict damage upon vulnerable DNA contained within each skin cell and ultimately skin cancer. Under normal circumstances, skin has a repair system that literally cuts out damaged DNA and replaces it with new, healthy code. Genetics play a role in one's ability to repair the damage. But too much ultraviolet damage may simply overwhelm the system.
Age and cumulative sun damage ultimately take a toll upon the body's ability to fix the damage. Eventually enough mutations occur that the formation of skin cancer becomes inevitable. Some individuals are more at risk than the general population because they are either genetically lacking the enzyme to heal the DNA damage (such as patients with Xeroderma Pigmentosa (XP); they are immunosuppressed (transplant patients), or have had a history of multiple skin cancers or precancerous growths.
Dimericine® is a drug that encapsulates a purified DNA repair enzyme (T4 endonuclease V) in a liposome capable of delivering the enzyme into skin to expedite the removal of DNA damage resulting from sun exposure. It can target the precancerous changes triggered by ultraviolet light and in doing so, hopefully prevent the development of skin cancer.
|
